RxDoctor Payments Data

Janelle Roethemeyer, MD

Internal Medicine · Saint Louis, MONPI 1417938929

Payments from drug & device makers

$924in general payments, 2019–2025

Across 52 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$109
  • Novo Nordisk$85
  • Sumitomo Pharma America, Inc.$85
  • Helsinn Therapeutics (U.S.), Inc.$78
  • Aclaris Therapeutics, Inc.$76
  • AbbVie$73
  • plus $419 from 15 others

What the payments were for

  • Food & beverage$89497%
  • Education$313%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$924 in reported general payments places this provider in the 70th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$72,686
Medicare patients
212
Services billed
1,655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban147$118,934
OzempicSemaglutide103$116,344
JardianceEmpagliflozin34$37,116
MyrbetriqMirabegron42$35,635
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$34,253
TrulicityDulaglutide24$30,619
MounjaroTirzepatide32$30,509
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr48$30,075
XareltoRivaroxaban26$27,945
JanuviaSitagliptin Phosphate21$26,522
TradjentaLinagliptin24$26,402
EntrestoSacubitril/Valsartan24$23,563
Semglee (Yfgn) PenInsulin Glargine-Yfgn40$23,147
LinzessLinaclotide29$21,163
Mirabegron ErMirabegron19$16,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$85$128,449116 claims
PfizerEliquis$109$118,934147 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arexvy, Breo Ellipta$40$91,720162 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$29$76,48879 claims
Lilly USA, LLCTrulicity, Mounjaro$56$61,12856 claims
Johnson & JohnsonXarelto$33$27,94526 claims
NovartisEntresto$13$23,56324 claims
AbbVieLinzess$73$21,16329 claims
AstraZenecaSymbicort$34$4,29513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →